FDA Approves First Drug for Non-Alcoholic Steatohepatitis (NASH): Resmetirom Explained │PHARMACOLOGY

This video looks into resmetirom, a new treatment for non-alcoholic steatohepatitis. Discover how resmetirom is revolutionizing the management of this chronic liver disease and offering hope to millions worldwide. We'll explore how it works and the latest clinical trial results.
Disclaimer: This RUclips channel is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. This should not be considered as a substitute for advice from a healthcare professional. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. The statements made about specific products are not to diagnose, treat, cure, or prevent disease.
References:
1. Alkhouri, N. (2020). Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196). Expert Opinion on Investigational Drugs, 29(2), 99-101. doi.org/10.108...
2. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. doi:10.1056/NEJMoa2309000
#medicalbreakthrough #fattyliver #liverdisease #hepatology #pharmacology #healthresearch #clinicaltrial #newtreatment

[@غربالالعازمين]

Fantastic ، thank you